Loviride
Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was primarily developed for the treatment of HIV and AIDS. It is a synthetic compound that inhibits the replication of HIV-1, the most common strain of the virus. Loviride was developed by Janssen Pharmaceutica, a Belgium-based pharmaceutical company.
History[edit]
Loviride was first synthesized in the early 1990s as part of a concerted effort to develop effective treatments for HIV and AIDS. It was one of the first NNRTIs to be developed, following the discovery of the reverse transcriptase enzyme and its role in the replication of HIV.
Mechanism of Action[edit]
As an NNRTI, Loviride works by binding to the reverse transcriptase enzyme, a key component in the replication of HIV. By binding to this enzyme, Loviride prevents the virus from transcribing its RNA into DNA, a necessary step in the replication process. This effectively halts the spread of the virus within the body.
Clinical Trials and Efficacy[edit]
Loviride has undergone several clinical trials to assess its efficacy and safety. In these trials, it has generally been found to be well-tolerated and effective at reducing viral load in patients with HIV. However, it is less potent than some other NNRTIs, and its use has been largely superseded by newer drugs in this class.
Side Effects and Contraindications[edit]
Common side effects of Loviride include nausea, vomiting, diarrhea, and rash. It may also cause changes in liver enzymes, which can lead to hepatotoxicity in some patients. Loviride is contraindicated in patients with severe liver disease.
Current Status[edit]
While Loviride was once a promising treatment for HIV and AIDS, it is no longer widely used due to the development of more effective and better-tolerated NNRTIs. However, it remains an important part of the history of HIV treatment and has contributed to our understanding of the virus and how to combat it.
This HIV related article is a stub. You can help WikiMD by expanding it.
Ad. Transform your life with W8MD's Budget GLP-1 injections from $29.99


W8MD offers medical weight loss programs including NYC medical weight loss and Philadelphia medical weight loss offering:
- Affordable GLP1 shots (generic and brand names) such as
- Wegovy NYC (Semaglutide)
- Zepbound NYC /
- Learn more: Budget GLP1 NYC & Philadelphia GLP1 shots
- Most insurances accepted
- Affordable GLP1 weight loss NYC such as Semaglutide starting from $29.99/week and $45.00/week (Tirzepatide) with insurance.
- Prescription weight loss NYC including:
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your physician weight loss journey today at our:
- NYC medical weight loss
- Philadelphia medical weight loss
- Call 718-946-5500 for NYC or 215-676-2334 for Philadelphia
Tags: Budget glp1 weight loss NYC, Zepbound NYC, Philadelphia medical weight loss, Wegovy NYC, Affordable glp1 shots Philadelphia
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
